667930-87-2

Upstream product

• 23286-70-6 5-amino-3-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 5650-07-7 3-methyl-1-phenyl-but-2-en-1-one 
• 1207507-51-4 C₁₈H₂₁N₃O₂ 
• 1293345-02-4 ethyl (5S)-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylate 
• 667920-89-0 ethyl 2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylate 

Downstream Products

• 667931-10-4 (5S)-N-[1-ethyl-1-(4-methylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant academic research and scientific papers

Novel and potent calcium-sensing receptor antagonists: Discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6, 7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent

The calcium-sensing receptor antagonist (CaSR) has been recognized as a promising target of anabolic agents for treating osteoporosis. In the course of developing a new drug candidate for osteoporosis, we found tetrahydropyrazolopyrimidine derivative 1 to